SavedAdd your journal

Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 3

Comparison of Intravitreal Ranibizumab Monotherapy versus Ranibizumab Combined with Laser Therapy in the Treatment of Diabetic Macular Edema

Diyabetik Maküla Ödemi Tedavisinde Ranibizumab Monoterapi ile Lazerle Kombine Ranibizumab Tedavilerinin Karşılaştırılması

Handan CANAN
Rana ALTAN YAYCIOĞLU
Pages
211–214
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: According to our study intravitreal ranibizumab monotherapy is more effective than combination of IVR with focal/grid laser therapy in the treatment of DME

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate visual acuity and macular thickness alterations after intravitreal ranibizumab (IVR) monotherapy and İVR injection combined with laser therapy in treatment of diabetic macular edema(DME).
📊
Key Findings & Data:Materials and Methods: Clinical records were retrospectively reviewed of 80 patients (98 eyes) who underwent intravitreal ranibizumab therapy for DME .
💡
Conclusion & Impact:Conclusion: According to our study intravitreal ranibizumab monotherapy is more effective than combination of IVR with focal/grid laser therapy in the treatment of DME
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate visual acuity and macular thickness alterations after intravitreal ranibizumab (IVR) monotherapy and İVR injection combined with laser therapy in treatment of diabetic macular edema(DME). Materials and Methods: Clinical records were retrospectively reviewed of 80 patients (98 eyes) who underwent intravitreal ranibizumab therapy for DME . The patients were divided into 2 groups according to the treatıment modality: Group I included 53 eyes treated with ranibizumab monotherapy and Group II included 45 eyes treated IVR with combiınation of focal/grid laser therapy. Patients were compared in terms of best-corrected visual acuity (BCVA) and central macular thickness (CMT) at 1st and 6th months. Results: Mean follow-up period was 14.8±5.4 months. The median (minimum-maximum) BCVA before the treatment in Group I and Group II was 0.7 (0.1-1.3) logıMAR and 1 (0.4-1.3) logMAR respectively. The visual acuity was 0.4 (0.1-1.3) logMAR and 0.7 (0.2-1.3) logMAR respectively at 6th month. The increase in BCVA was statistically significant in group I (p=0.0001). The median (minimummaximum) CMT before the treatment in Group I and Group II was 487 ?m and 493 ?m respectively. The CMT was 284 ?m and 352 ?m respectively at 6th month. The decrease in CMT was statistically significant in group I (p=0.001). Conclusion: According to our study intravitreal ranibizumab monotherapy is more effective than combination of IVR with focal/grid laser therapy in the treatment of DME

Özet

Amaç: Diyabetik maküla ödemi (DMÖ) tedavisinde tek başına intravitreal ranibizumab (IVR) enjeksiyonu ile lazer ve IVR kombinasyon tedavisi sonrası santral maküla kalınlığı (SMK) değişimi ve görme keskinliği sonuçlarının değerlendirilmesi.Gereç ve Yöntem: Diyabetik maküla ödemi nedeniyle intravitreal ranibizumab uygulanan 80 olgunun (98 göz) kayıtları retrospektif olarak incelendi. Hastalar uygulanan tedaviye göre 2 gruba ayrılarak değerlendirildi: I. grup (53 göz) tek başına ranibizumab ile tedavi edilenler; II. grup (45 göz) ranibizumab ile kombine fokal/grid lazer tedavisi uygulananlar. Hastaların 1. ay ve 6. aydaki en iyi düzeltilmiş görme keskinliği (EİDGK) ve SMK değerleri karşılaştırıldı.Bulgular: Ortalama takip süresi 14.8±5.4 aydı. Grup I ve Grup II'de tedavi öncesi ortalama EİDGK medyan değerleri (en küçük-en büyük) sırasıyla 0.7 (0.1-1.3) logMAR ve 1 (0.4-1.3) logMAR , tedavi sonrası 6. ayda sırasıyla 0.4 (0.1-1.3) logMAR ve 0.7 (0.2-1.3) logMAR ölçüldü. Grup I'de görme keskinliğindeki artış istatistiksel olarak anlamlıydı (p=0.0001). Grup I ve Grup II'de tedavi öncesi medyan SMK değerleri sırasıyla 487 ?m ve 493 ?m, tedavi sonrası 6. ayda sırasıyla 284 ?m ve 352 ?m olarak ölçüldü. Grup I'de SMK değerlerindeki azalma istatistiksel olarak anlamlıydı (p=0.0001).Sonuç: Çalışmamızda DMÖ tedavisinde intravitreal ranibizumab monoterapisi, IVR ile kombine fokal/grid lazer tedavisine göre daha etkili bulunmuştur

🔖

Cite This Article

CANAN, H., YAYCIOĞLU, R. A. (2015). Comparison of Intravitreal Ranibizumab Monotherapy versus Ranibizumab Combined with Laser Therapy in the Treatment of Diabetic Macular Edema. Retina-Vitreus, Cilt: 23 - Sayı: 3, 211–214. https://ajindex.com/articles/308008

References (7)

  1. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998;105:998-1003.
  2. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy.XV.The long-term incidence of macular ede- ma. Ophthalmology 1995;102:7-16. Early Treatment Diabetic Retinopathy Study research group. Photoco- agulation for diabetic macular edema.Early Treatment Diabetic Reti- nopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema. Relations- hip of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol 1995;113:1144-55. Diabetic Retinopathy Clinical Research Network. Three-year follow up of a randomized trial comparing focal/grid photocoıagulation and int- ravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-51. Diabetic Retinopathy Clinical Research Network. Factors asısociated with improved and worsening of visual acuity 2 years after focal/ grid photocoagulation for diabetic macular edema. Ophthalmology 2010;117:946-53. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, et al.: A phase II randomized cinical trial of intra- vitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7.
  3. Massin P, Bandello F, Garweg J, et al. Safety and efficacy of ranibi- zumab in diabetic macular edema (RESOLVE study). Diabetes Care 2010;33:2399-405.
  4. Nguyen QD, Shah SM, Heier JS, et al. Primary End Point(Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-8.
  5. Nguyen QD, Shah SM, Khwaja AA,et al.Two-year out comes of the ra- nibizumab for edema of the mAcula in diabetes (READ-2) study. Oph- thalmology 2010;117:2146-51. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabe- tic macular edema. Ophthalmology 2010;117:1064-77.
  6. Elman MJ, Bressler NM, Qin H, et al.; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabe- tic macular edema. Ophthalmology 2011;118:609-14.
  7. Kernt M, Cserhati S, Seidensticker F, et al. Improvement of diabetic retin